Free Helpline
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Explore the different types of multiple myeloma, including IgG, IgA, light-chain, IgM, IgD, and IgE myeloma. Understand smoldering vs. active forms and diagnostic approaches.
Multiple myeloma is a type of blood cancer that affects plasma cells. Plasma cells are a crucial part of your immune system, found in the bone marrow. Their primary role is to produce antibodies, also known as immunoglobulins, which help your body fight off infections and diseases. In multiple myeloma, these plasma cells grow uncontrollably and multiply rapidly. They produce an abnormal protein, called a monoclonal protein (M protein), which doesn't function like healthy antibodies and can't effectively combat pathogens. This overproduction and accumulation of abnormal plasma cells can lead to various health complications.
It's important to distinguish between two main stages or forms of multiple myeloma: Smoldering Multiple Myeloma (SMM) and Active Multiple Myeloma.
SMM is considered a precancerous condition. Individuals with SMM do not experience any symptoms, and often, it is discovered incidentally during routine medical check-ups when blood or urine tests reveal elevated protein levels. Further investigations then confirm the presence of SMM. Unlike active myeloma, SMM typically does not require immediate treatment. Instead, doctors usually recommend regular monitoring to detect any signs of progression to active myeloma. The risk of SMM progressing to active myeloma varies among individuals. Factors such as higher M protein levels and a greater percentage of plasma cells in the bone marrow can indicate a higher risk of progression within a few years. Research suggests that SMM carries a significant risk of progressing to active myeloma: approximately 50% within 5 years and 65% within 10 years. However, about 25% of people with SMM may never develop symptomatic myeloma.
Active multiple myeloma is characterized by the presence of symptoms and organ damage caused by the cancerous plasma cells. Common symptoms can include bone pain, fatigue, nausea, and increased susceptibility to infections. Active myeloma requires prompt medical attention and treatment to manage the disease and alleviate symptoms.
Multiple myeloma is primarily classified based on the type of immunoglobulin that is overproduced by the abnormal plasma cells. Healthy plasma cells produce various types of immunoglobulins to fight different pathogens. In contrast, myeloma cells produce only one specific type of immunoglobulin, leading to an excess of that particular type. There are five main types of immunoglobulins, and thus, five primary types of multiple myeloma:
This is the most prevalent type of multiple myeloma, accounting for approximately 57% of all cases, according to a 2020 study. In IgG myeloma, the overproduced immunoglobulin is Immunoglobulin G (IgG). IgG is the most abundant type of antibody in the blood and plays a vital role in the immune response.
IgA myeloma is the second most common type, making up about 20% of myeloma cases. In this type, the overproduced immunoglobulin is Immunoglobulin A (IgA). Research from 2020 suggests that IgA myeloma might be associated with lower long-term survival rates compared to IgG myeloma.
Light-chain myeloma is the third most common type, representing about 15% of cases. This type is a bit different because the myeloma cells produce only the 'light chains' of immunoglobulins, which are smaller components, rather than complete immunoglobulin molecules. These light chains are also known as Bence-Jones proteins. A challenge with light-chain myeloma is that it may not always lead to elevated levels of complete immunoglobulins in the blood or urine, making it potentially harder to detect through standard tests. Doctors may need to rely on bone marrow scans like CT or PET scans for diagnosis.
IgM myeloma is much rarer, accounting for only about 1% of all multiple myeloma cases. In this type, the overproduced immunoglobulin is Immunoglobulin M (IgM). While it shares similarities with IgG and IgA myeloma, the overproduction of IgM can sometimes lead to other related disorders, such as Waldenstrom macroglobulinemia.
This is another rare type of multiple myeloma, comprising less than 2% of cases. IgD myeloma is more frequently observed in males and tends to affect individuals at a younger age. It is often considered more aggressive than other types of myeloma.
IgE myeloma is the rarest form of multiple myeloma, accounting for a mere 0.1% of cases. This type is characterized by the overproduction of Immunoglobulin E (IgE). IgE myeloma is typically very aggressive and is associated with lower survival rates compared to other types.
Diagnosing multiple myeloma involves a combination of medical history, physical examination, and various laboratory and imaging tests. These may include:
Treatment for multiple myeloma depends on the type, stage, and the patient's overall health. Options may include:
For Smoldering Multiple Myeloma (SMM), the approach is often watchful waiting with regular monitoring, as immediate treatment may not be necessary and could lead to unnecessary side effects.
If you experience persistent symptoms such as unexplained bone pain, extreme fatigue, frequent infections, or unexplained weight loss, it is crucial to consult a doctor. Early detection and diagnosis are key to effective management and treatment of multiple myeloma.
This section adds practical context and preventive advice to help readers make informed healthcare decisions. It is important to verify symptoms early, consult qualified doctors, and avoid self-medication for persistent health issues.
Maintaining healthy routines, following prescribed treatment plans, and attending regular checkups can improve outcomes. If symptoms worsen or red-flag signs appear, immediate medical evaluation is recommended.
Track symptoms and duration.
Follow diagnosis and treatment from a licensed practitioner.
Review medication side effects with your doctor.
Seek urgent care for severe warning signs.
Learn about potential side effects of CML treatments like TKIs, interferon, chemotherapy, and stem cell transplants. Understand what to expect and how to communicate with your doctor for effective management.
April 1, 2026
Discover essential support resources, financial aid options, and community connections for individuals navigating life with Chronic Myeloid Leukemia (CML). Find practical advice and empathetic guidance.
April 1, 2026
Explore targeted therapy for multiple myeloma. Learn how these precision treatments work, their types, potential side effects, and how they're used alongside other therapies to manage this blood cancer.
April 1, 2026